Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | RHOA | P61586 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21926389 | 1.00 | MGLL (0.71) | MGLLKMT2AMEN1GLAHSD17B10 | |
| SCHEMBL1720091 | 0.92 | MGLL (0.84) | MGLLKMT2AMEN1 | |
| SCHEMBL5479680 | 0.92 | ALDH1A1 (0.62) | MGLLKMT2AMEN1GLAHSD17B10 | |
| SCHEMBL21926514 | 0.89 | ALDH1A1 (0.70) | MGLLKMT2AMEN1GLAHSD17B10 | |
| SCHEMBL21926483 | 0.87 | ALDH1A1 (0.72) | MGLLGLAHSD17B10L3MBTL1ALDH1A1 | |
| SCHEMBL21926486 | 0.87 | ALDH1A1 (0.76) | MGLLL3MBTL1ALDH1A1RHOA | |
| SCHEMBL21926392 | 0.87 | MEN1 (0.62) | MGLLKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL21928849 | 0.87 | HSD11B1 (0.71) | MGLLKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL21926990 | 0.86 | HPGD (0.58) | MGLLKMT2AMEN1GLAHSD17B10 | |
| SCHEMBL21928884 | 0.86 | KDM2B (0.58) | MGLLKMT2AMEN1GLAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131125-A1 | ARYL-PIPERIDINE DERIVATIVES | ARTAX BIOPHARMA INC. | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131125-A1 | ARYL-PIPERIDINE DERIVATIVES | CD4, CD2, CCR1 | MGLL 4818/4885KMT2A 1460/4885MEN1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.